-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS: CSPC Group's (01093) quarterly results are in line with expectations to maintain a “buy” rating with a target price of HK$11.8

Zhitongcaijing·11/20/2026 06:25:01
Listen to the news

The Zhitong Finance App learned that UBS released a research report saying that the third quarter results announced by CSPC Group (01093) were generally in line with market expectations, and that the bank maintained a “buy” rating and target price of HK$11.8.

The bank pointed out that the company's third-quarter revenue was 6.7 billion yuan, up 0.7% year on year and down 45% from quarter to quarter, higher than the bank's forecast of 6.2 billion yuan, which is roughly in line with market expectations of 6.7 billion yuan; net profit attributable to shareholders was 982 million yuan, up 1.9% year on year and 81.2% from quarter to quarter, higher than the bank's forecast of 239 million yuan and market expectations of 864 million yuan. Higher profits than market expectations were mainly driven by other revenue, while operating profit fell between the bank's expectations and market expectations. Gross margin and operating profit margin increased by 1 percentage point and 1.3 percentage points to 66.6% and 14.5%, respectively; R&D expenditure ratio increased 1.5 percentage points year over year to 24.2%, while sales and administrative expenditure ratio decreased 1.8 percentage points to 27.9% year on year.

In terms of segments, revenue from APIs, functional foods and others was 1.1 billion yuan, down 24% year on year and 17% quarterly, lower than market expectations of 1.4 billion yuan. Although license fee revenue was lower than market expectations (495 million yuan), sales of finished drugs were higher than market expectations (4.8 billion yuan).

The bank believes that the 2027 growth prospects will be supported by central nervous system business resilience and oncology product portfolio updates. Management expects more than 10 products and indications to be approved next year, but weak APIs are still a drag. The bank raised its 2026 earnings forecast per share by 16% to 0.67 yuan due to better-than-expected earnings for the third quarter.